Evolus, Inc. (EOLS)
6.71
+0.08
(+1.21%)
USD |
NASDAQ |
Nov 17, 16:00
6.77
+0.06
(+0.89%)
After-Hours: 20:00
Evolus Enterprise Value : 562.41M for Nov. 16, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 16, 2026 | 562.41M |
| November 13, 2026 | 584.23M |
| November 12, 2026 | 598.79M |
| November 11, 2026 | 614.66M |
| November 10, 2026 | 574.31M |
| November 09, 2026 | 585.56M |
| November 06, 2026 | 573.98M |
| November 05, 2026 | 573.32M |
| November 04, 2026 | 617.97M |
| November 03, 2026 | 611.35M |
| November 02, 2026 | 597.46M |
| October 30, 2026 | 610.03M |
| October 29, 2026 | 621.27M |
| October 28, 2026 | 628.88M |
| October 27, 2026 | 611.35M |
| October 26, 2026 | 598.12M |
| October 23, 2026 | 587.54M |
| October 22, 2026 | 614.00M |
| October 21, 2026 | 613.34M |
| October 20, 2026 | 611.35M |
| October 19, 2026 | 610.69M |
| October 16, 2026 | 593.49M |
| October 15, 2026 | 624.58M |
| October 14, 2026 | 601.43M |
| October 13, 2026 | 620.61M |
| Date | Value |
|---|---|
| October 12, 2026 | 636.49M |
| October 09, 2026 | 635.16M |
| October 08, 2026 | 639.79M |
| October 07, 2026 | 635.82M |
| October 06, 2026 | 612.01M |
| October 05, 2026 | 617.97M |
| October 02, 2026 | 596.14M |
| October 01, 2026 | 632.52M |
| September 30, 2026 | 653.02M |
| September 29, 2026 | 647.08M |
| September 28, 2026 | 645.10M |
| September 25, 2026 | 645.76M |
| September 24, 2026 | 638.50M |
| September 23, 2026 | 647.74M |
| September 22, 2026 | 664.25M |
| September 21, 2026 | 647.08M |
| September 18, 2026 | 638.50M |
| September 17, 2026 | 648.40M |
| September 16, 2026 | 647.08M |
| September 15, 2026 | 641.80M |
| September 14, 2026 | 643.12M |
| September 11, 2026 | 637.18M |
| September 10, 2026 | 641.80M |
| September 09, 2026 | 685.37M |
| September 08, 2026 | 705.84M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ANI Pharmaceuticals, Inc. | 1.794B |
| Corcept Therapeutics, Inc. | 7.209B |
| Veru, Inc. | 12.36M |
| Johnson & Johnson | 707.55B |
| Eli Lilly & Co. | 1.392T |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -12.52M |
| Revenue (Quarterly) | 77.95M |
| Total Expenses (Quarterly) | 90.47M |
| EPS Diluted (Quarterly) | -0.1894 |
| Gross Profit Margin (Quarterly) | 63.00% |
| Profit Margin (Quarterly) | -16.06% |
| Earnings Yield | -7.05% |
| Normalized Earnings Yield | -7.160 |